ly3214996
Small moleculeexperimental
Clinical trial activity
10 trials · 11 clinical orgs · 0 marketing orgs
Phase 1
8
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Sep 1, 2016 (NCT02857270)
Timeline
Indications
Studied for
- Adenocarcinoma · Phase 1/Phase 2
- Biliary Tract Neoplasms · Phase 1
- Carcinoma, Non-Small-Cell Lung · Phase 1
- Colonic Neoplasms · Phase 1/Phase 2
- Colorectal Neoplasms · Phase 1/Phase 2
- Endometrial Neoplasms · Phase 1
- Glioblastoma · Early Phase 1
- Glioma · Early Phase 1
- Healthy Volunteers · Phase 1
- Leukemia, Lymphocytic, Chronic, B-Cell · Phase 1
- Leukemia, Myeloid, Acute · Phase 1
- Lymphoma, B-Cell, Marginal Zone · Phase 1
- Lymphoma, Mantle-Cell · Phase 1
- Melanoma · Phase 1
- Mutation · Phase 2
- Neoplasm Metastasis · Phase 2
- Neoplasms · Phase 2
- Ovarian Neoplasms · Phase 1
- Pancreatic Neoplasms · Phase 2
- Proto-Oncogene Proteins B-raf · Phase 2
- Waldenstrom Macroglobulinemia · Phase 1
Mechanism of action
- MAP kinase ERK1INHIBITOR
MAPK3 inhibitor
- MAP kinase ERK2INHIBITOR
MAPK1 inhibitor
Mitogen-activated protein kinase; ERK1/ERK2 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
Cn1nccc1Nc1nccc(-c2cc3c(s2)C(C)(C)N(CCN2CCOCC2)C3=O)n1- Mol. weight
- 453.57 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4650285 ↗
Also known as
- ly3214996
- ly3214996
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04916236 | Phase 1 | Oct 31, 2021 | Lustgarten Foundation, Netherlands Cancer Institute |
| NCT04956640 | Phase 1 | Jul 19, 2021 | Eli Lilly, Loxo Oncology |
| NCT04616183 | Phase 1/Phase 2 (Phase 2) | Dec 2, 2020 | National Cancer Institute (NCI), University of Texas at Houston |
| NCT04534283 | Phase 2 | Sep 28, 2020 | Eli Lilly, Indiana University |
| NCT04386057 | Phase 2 | Jun 30, 2020 | Eli Lilly, Harvard University |
| NCT04391595 | Early Phase 1 (Phase 1) | May 31, 2020 | Barrow Neurological Institute, Ivy Brain Tumor Center, University of Arizona |
| NCT04081259 | Phase 1 | Sep 30, 2019 | Eli Lilly, Harvard University |
| NCT04043845 | Phase 1 | Aug 31, 2019 | Eli Lilly, Harvard University |
| NCT04033341 | Phase 1 | Aug 1, 2019 | Eli Lilly |
| NCT02857270 | Phase 1 | Sep 1, 2016 | Eli Lilly |
Showing 10 of 10 trials
Page 1 / 1
Organizations
Research & Development (11)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Eli Lilly | For profit | 7 | 3 | 2 | 2016 |
| Harvard University | Academic/Hospital | 3 | 3 | 2 | 2019 |
| Barrow Neurological Institute | Academic/Hospital | 1 | 1 | 1 | 2020 |
| Indiana University | Academic/Hospital | 1 | 1 | 1 | 2020 |
| Ivy Brain Tumor Center | Academic/Hospital | 1 | 0 | 1 | 2020 |
| Loxo Oncology | For profit | 1 | 0 | 1 | 2021 |
| Lustgarten Foundation | Academic/Hospital | 1 | 0 | 1 | 2021 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2020 |
| Netherlands Cancer Institute | Academic/Hospital | 1 | 1 | 1 | 2021 |
| University of Arizona | Academic/Hospital | 1 | 0 | 1 | 2020 |
| University of Texas at Houston | Academic/Hospital | 1 | 1 | 1 | 2020 |
11 organizations
Page 1 / 1